Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Lyons

Rheumatology Nashville, TN Medical Doctor

NPI 1730474321 CMS profile 839712

4230 Harding Pike Ste 501, Nashville, TN 37205

Open in the dashboard

General payments

$6,259

351 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elizabeth Lyons of Nashville, TN is reported in the CMS Open Payments database as having received $6,259 across 351 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $100 1
2024 General $63 3
2023 General $20 1
2022 General $365 17
2021 General $1,912 109
2020 General $1,808 100
2019 General $1,991 120

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Lyons
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Elizabeth Lyons were reported at $100. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Elizabeth Lyons Rheumatology median Middle half National median
2019 $1,991 $744 $153–$2,687 $163
2020 $1,808 $462 $98–$2,027 $114
2021 $1,912 $531 $101–$2,153 $132
2022 $365 $627 $125–$2,303 $149
2023 $20 $741 $145–$2,524 $160
2024 $63 $830 $166–$2,660 $164
2025 $100 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,354 75 payments
  2. UCB, Inc. $643 32 payments
  3. Lilly USA, LLC $608 31 payments
  4. AbbVie, Inc. $589 33 payments
  5. Novartis Pharmaceuticals Corporation $526 34 payments
  6. Janssen Biotech, Inc. $356 21 payments
  7. GlaxoSmithKline, LLC. $339 19 payments
  8. E.R. Squibb & Sons, L.L.C. $247 15 payments
  9. Pfizer Inc. $205 11 payments
  10. Genentech USA, Inc. $161 10 payments
  11. Other $1,231 70 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,194 347 payments
  2. Education $65 4 payments
Products named General payments · program years 2019–2025
  1. Prolia $564 33 payments
  2. Cimzia $542 31 payments
  3. COSENTYX $526 34 payments
  4. TALTZ $487 29 payments
  5. EVENITY $412 19 payments
  6. BENLYSTA $339 19 payments
  7. Enbrel Inflammation $265 18 payments
  8. Enbrel Inflammation $263 14 payments
  9. HUMIRA $255 16 payments
  10. ORENCIA $247 15 payments
  11. Other $3,619 209 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

4,484

Median for Rheumatology: 1,511

Drug cost

$2,137,829

Median for Rheumatology: $1,139,948

Branded share of claims

23.8%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 71 $552,854
Cosentyx Sensoready (2 Pens) Secukinumab Brand 37 $272,600
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 12 $227,128
Otezla Apremilast Brand 35 $172,306
Orencia Clickject Abatacept Brand 26 $147,384
Taltz Autoinjector Ixekizumab Brand 21 $142,821
Rinvoq Upadacitinib Brand 23 $142,388
Simponi Golimumab Brand 19 $118,545
Humira(Cf) Pen Adalimumab Brand 15 $106,096
Humira(Cf) Adalimumab Brand 13 $85,336

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$1,744,374

Of which drugs: $1,590,757

Medicare patients

665

Average age 74

Services billed

141,493

584 women, 81 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 60%
Osteoporosis 46%
Depression 26%
Ischemic heart disease 21%
Chronic kidney disease 21%
Diabetes 18%
Atrial fibrillation 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 Office 16 9,300 $315,330
Injection, tocilizumab, 1 mg J3262 Office 13 65,764 $310,288
Injection, denosumab, 1 mg J0897 Office 114 11,760 $238,632
Injection, infliximab, excludes biosimilar, 10 mg J1745 Office 15 6,440 $156,486
Injection, golimumab, 1 mg, for intravenous use J1602 Office 18 14,922 $136,453
Vaccine for influenza for injection into muscle 90662 Office 45 46 $3,564
Injection, zoledronic acid, 1 mg J3489 Office 40 200 $952
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 44 1,907 $427
Injection, methylprednisolone acetate, 1 mg J1010 Office 25 2,860 $285
Injection, methylprednisolone sodium succinate, up to 40 mg J2920 Office 27 53 $171

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TALTZ
  • Lilly USA, LLC $48
$48 21 —
Otezla
  • Amgen Inc. $8
$8 35 —
Enbrel
  • Amgen Inc. $8
$8 71 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

351 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record